Navigation Links
Phase 3 Trial of Nexavar in Chemotherapy-Naive Patients with Advanced Melanoma Does Not Meet Primary Endpoint
Date:4/26/2009

overnment agencies and individual investigators as a single agent or combination treatment in a wide range of cancers, including lung cancer, breast cancer and as an adjuvant therapy for kidney and liver cancer.

Important Safety Considerations For Patients Taking Nexavar

Based on the currently approved U.S. package insert for the treatment of patients with unresectable hepatocellular carcinoma and advanced kidney cancer, hypertension may occur early in the course of therapy and blood pressure should be monitored weekly during the first six weeks of therapy and treated as needed. In HCC patients, bleeding with a fatal outcome from any site was reported in 2.4% for Nexavar and 4% in placebo. The incidence of treatment-emergent cardiac ischemia/infarction was 2.7% for Nexavar vs. 1.3% for placebo. In RCC patients, incidence of bleeding regardless of causality was 15% for Nexavar vs. 8% for placebo and the incidence of treatment-emergent cardiac ischemia/infarction was 2.9% for Nexavar vs. 0.4% for placebo. Most common adverse events greater than or equal to 20% related to Nexavar for both HCC and RCC were fatigue, weight loss, rash/desquamation, hand-foot skin reaction, alopecia, diarrhea, nausea, and abdominal pain. Grade 3/4 adverse events in HCC and RCC patients, respectively, were 45% for Nexavar vs. 32% for placebo and 38% for Nexavar and 28% for placebo. Women of child-bearing potential should be advised to avoid becoming pregnant and advised against breast-feeding. In cases of any severe or persistent side effects, temporary treatment interruption, dose modification or permanent discontinuation should be considered.

For information about Nexavar including U.S. Nexavar prescribing information, visit www.nexavar.com or call 1.866.NEXAVAR (1.866.639.2827).

About Bayer HealthCare Pharmaceuticals Inc.

Bayer HealthCare Pharmaceut
'/>"/>

SOURCE Onyx Pharmaceuticals, Inc.; Bayer HealthCare Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Human Genome Sciences Reports Positive Late-Breaker Results at EASL from ACHIEVE Phase 3 Trials of Albuferon(R) in Patients with Chronic Hepatitis C
2. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
3. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
4. Ridge Diagnostics, Inc. Awarded Phase 2 National Science Foundation Grant
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Addrenex Pharmaceuticals Reports Positive Results in Second Phase 3 Study of ADHD Medication
7. Final Results of Boceprevir Phase II HCV SPRINT-1 Study Showed Significantly Higher SVR Rates Compared to Standard of Care in Treatment-Naive Genotype 1 Hepatitis C Patients
8. Phase 1 Trial of Whole-Parasite Malaria Vaccine to Begin
9. BioMarin Initiates Phase 1/2 Clinical Trial for GALNS for Morquio A Syndrome
10. ImQuest BioSciences Receives Phase I SBIR Grant to Develop a Novel Hepatitis C Virus Therapeutic Agent
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Md. , Aug. 29, 2014  United Therapeutics ... the U.S. District Court for the District of ... favor in the company,s case against Sandoz, Inc. regarding ... Peter Sheridan ruled that U.S. Patent No. ... and enjoined Sandoz from marketing its generic product until ...
(Date:8/29/2014)... Aug. 29, 2014  Unilife Corporation ("Unilife" or "Company") ... that it intends to release its financial results for ... 30, 2014 after market trading ends on Tuesday, September ... conference call for 4:30 p.m. U.S. EDT on Tuesday, ... a.m. AEST), to review the Company,s financial results, commercial partnerships, ...
(Date:8/29/2014)... UNION CITY, Calif. , Aug. 29, 2014 /PRNewswire/ ... products company manufacturing point-of-care blood instrumentation and consumables to ... Clint Severson , Chairman and Chief Executive Officer, ... Annual Best Ideas Conference 2014 on Tuesday, September 9, ... held at the Omni Berkshire Place Hotel in ...
Breaking Medicine Technology:District Court Decision Received In Remodulin Patent Case 2Unilife Corporation to Announce Financial Results for Fiscal Year 2014 Fourth Quarter and Year End on Tuesday, September 9, 2014 2Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2
(Date:8/30/2014)... 30, 2014 Seniors Guide, the comprehensive guide ... focus on Alzheimer’s Disease, Dementia, and Memory Loss . ... public of being diagnosed with the Alzheimer’s, inspired Seniors Guide ... Be Me”. The movie, out on October 14, 2014, ... his diagnosis of the disease – which inspires a final ...
(Date:8/30/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
(Date:8/30/2014)... "My niece developed a nighttime fever, and I ... fever might get worse," said an inventor from Montgomery, ... how she was doing, I developed this monitoring system." ... a child's temperature. The unit instantly alerts parents if ... medical care can be given, which is designed to ...
(Date:8/30/2014)... lead extraction (TLE) is clinically successful in more than ... Lead Extraction ConTRolled (ELECTRa) registry presented for the first ... Grazia Bongiorni, chair of the registry,s executive committee. , ... devices (CIED) implant procedures has grown in recent years. ... increased and leads are often the cause. TLE is ...
(Date:8/30/2014)... The new review published by Daily Gossip reveals ... Brimeyer, who wanted to make her guide accessible to sufferers ... now easy to find in the form of an eBook, ... author of the new method shares all her tips and ... in its review that the leaky gut syndrome can be ...
Breaking Medicine News(10 mins):Health News:Alzheimer’s Disease and Dementia Focus on Retirement Website SeniorsGuideOnline.com 2Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2
... 7 MQ Associates, Inc.,("MedQuest"), a leading national provider ... third quarter and nine months ended,September 30, 2007. ... 2007, representing,a decrease of $8.1 million, or 11.9%, from ... Net revenue was $186.5 million for the nine months,ended ...
... for retinopathy laser treatment, study finds , WEDNESDAY, Nov. ... diabetes, the drug fenofibrate reduces the need for laser ... loss and blindness among working-age adults worldwide. , Australian ... ages 50-75, who received either 200 milligrams per day ...
... 7 MED3OOO, Inc., a national healthcare,management ... Molina,Healthcare of California to provide Revenue Cycle ... communications technology, and,coding services. Molina Healthcare ... managed,healthcare companies serving patients who have traditionally ...
... BURLINGTON, Mass., Nov. 7 LeMaitre Vascular,Inc. (Nasdaq: ... medical,devices and implants for the treatment of peripheral ... Adams inaugural Cardiovascular,Conference on Tuesday, November 13, 2007, ... David B. Roberts, President of LeMaitre Vascular, ...
... Changes reflect company,s focus on growth and value ... Technologies, Inc. ("EAU",or "Company") (OTC Bulletin Board: EAUI), ... Technology" to numerous industries,including food processing, agriculture, dairy ... help the organization,better meet the needs of its ...
... cholesterol-lowering drug appears to disrupt sleep patterns of some ... Sessions 2007. , The findings are significant because sleep ... adverse health consequences, such as promoting weight gain and ... the study and an associate professor of medicine and ...
Cached Medicine News:Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 2Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 3Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 4Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 5Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 6Health News:MQ Associates, Inc. Announces Results for the Third Quarter and Nine Months Ended September 30, 2007 7Health News:Diabetes Drug Helps Protect Patients' Eyes 2Health News:Molina Medical Group Selects MED3OOO 2Health News:EAU Technologies Announces New Chairman of the Board and Board Leadership 2Health News:EAU Technologies Announces New Chairman of the Board and Board Leadership 3Health News:EAU Technologies Announces New Chairman of the Board and Board Leadership 4Health News:Cholesterol-lowering drug linked to sleep disruptions 2
... cannula with 30 gauge, 4.76 mm tip is ... Cannula is attached to a luer lock high ... inch long), for use with high viscosity substances. ... using visco elastic materials. Flattened, angled tip of ...
20 gauge x 25 mm cannula with 30 degree x 5 mm tip. 30 gauge cannula extends into hub 2 mm from end of hub. 10 per box....
Developed for oculoplastic procedures for corneal and scleral protection. Dimensions enable protector to rest on the sclera and not on the cornea. Easily removed with Bishop-Harmon Forceps. Individua...
The moist air humidifying chamber is designed for the infusion of humidified air during phakic fluid air exchange. Sterile single-use. 10 per box. Most popular size or model....
Medicine Products: